The Effect Metacognitive Therapy on patient with Multiple Sclerosis

Not Applicable

• Conditions: Multiple SCLEROSIS.; Demyelinating diseases of the central nervous system; G35-G37

• Registration Number: IRCT2015091624054N1
• Lead Sponsor: Investigator

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

Main inclusion and exclusion criteria:
The final diagnosis of developing MS by the neurologist, signing a written consent form to participate in the study, having at least a diploma and achieving scores 1 to 4 in EDSS diagnosed by the neurologist.
Exclusion criteria: Receiving psychological treatments at least six month prior to entering the study, a history of metabolic diseases like thyroid and absence of more than two sessions.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Metacognitive Components. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: Metacognition Questionnaire -30 (MCQ-30).;Resiliency. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: Connor and Davidson Resilience Scale (CD-RISC).;Self-Efficacy. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: General Self-Efficacy Questionnaire.;Defense Mechanisms. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: Defense Styles Questionnaire (DSQ).